Background {#section5-2050312119857353}
==========

Adverse drug events (ADEs) have been one of the major public health concerns to patients and health care professionals. Hospital adverse events are an important source of morbidity and mortality in different countries and settings and represent an important item of expenditure for health care systems and their prevention could be associated with a relevant cost saving.^[@bibr1-2050312119857353]^ One of the specific types of ADE is drug--drug interaction (DDI).^[@bibr2-2050312119857353]^ It is defined as pharmacological or clinical response to the administration of a drug combination which is different from that expected from the known effects of the two agents when given alone. The clinical result of a DDI may manifest as antagonism, synergism, or idiosyncratic.^[@bibr3-2050312119857353]^ It can be divided into pharmacodynamic (PD) and pharmacokinetic (PK) interactions. PD interactions occur when the combination of medications causes additive or antagonistic pharmacological effects and influence efficacy. PK interactions occur when there are changes in absorption, distribution, metabolism, and elimination.^[@bibr4-2050312119857353]^ They are often predictable and, therefore, avoidable or manageable.^[@bibr5-2050312119857353],[@bibr6-2050312119857353]^

DDIs are more frequent in patients who are elder, hospitalized for a longer period of time, and/or receive more drugs per day.^[@bibr7-2050312119857353][@bibr8-2050312119857353]--[@bibr9-2050312119857353]^ Maybe due to comorbid conditions, chronic therapeutic regimens, polypharmacy, and frequent modification in therapy, hospitalized patients are more likely affected by potential drug--drug interactions (pDDIs). The prevalence of pDDIs is close to 40% in patients taking five medications and exceeds 80% in patients taking seven or more medications.^[@bibr10-2050312119857353],[@bibr11-2050312119857353]^

The incidence of cardiovascular diseases has significantly increased in the recent decades and considered as a leading cause of deaths worldwide.^[@bibr12-2050312119857353]^ Various studies suggest that cardiovascular patients are more often reported with pDDIs as compared to patients with other diseases. The possible reasons behind include older age, multiple drug regimens, PK or PD nature of drugs used in cardiology, and the influence of heart disease on drug metabolism.^[@bibr13-2050312119857353],[@bibr14-2050312119857353]^ The pDDIs for a particular cardiovascular drug vary with the individual, the disease being treated, and the extent of exposure to other drugs.^[@bibr15-2050312119857353],[@bibr16-2050312119857353]^

Different practice models and experience showed that the clinical pharmacists have a major role in preventing DDIs; especially by evaluating physicians' prescriptions for possible DDI.^[@bibr17-2050312119857353],[@bibr18-2050312119857353]^ Therefore, integrated professional interaction should be encouraged between health care professionals in order to optimize drug safety. Vigilance by health care workers, such as clinicians, pharmacists, and nurses in detecting, diagnosing, and reporting DDIs, particularly in at-risk individuals such as cardiac patients, is also vital for continued drug safety monitoring.

As a result, pDDIs have become a common concern and an important concept in terms of an appropriate prescription process.^[@bibr16-2050312119857353],[@bibr19-2050312119857353],[@bibr20-2050312119857353]^ Hence, robust and accurate information regarding the potential adverse impacts of co-administration of drugs is critical for reducing the health impacts and costs of adverse events.^[@bibr9-2050312119857353]^ Different studies have been conducted to develop practical decision, support tools, and improve clinicians' knowledge of prevalent and clinically important pDDIs encountered in their daily practice. In Ethiopia, inappropriate prescription of drugs with potential interactions causing serious risks to patient health has not been adequately studied among cardiac patients. Hence, this study sought to determine the type, prevalence, and characteristics of pDDIs and associated factors among inpatients receiving cardiovascular medications at medical wards of Jimma University Medical Center (JUMC).

Methods {#section6-2050312119857353}
=======

Study design and setting {#section7-2050312119857353}
------------------------

A hospital-based prospective observational study design was conducted during February to March 2017 at the internal medicine wards of JUMC among adults hospitalized with cardiac disorder who fulfill the inclusion criteria. JUMC is the only teaching and referral hospital in the southwestern part of Ethiopia with a bed capacity of 600. Geographically, it is located in the Jimma town 352 km southwest of Addis Ababa, the capital. It provides services for approximately 9000 inpatient and 80,000 outpatient clients per year with a catchment population of about 15 million people.

Study population {#section8-2050312119857353}
----------------

Hospitalized cardiac patients aged 18 years or older admitted to the internal medicine wards with a hospital stay of at least 24 h and those prescribed least two medications of any type were enrolled for the study. Patients visiting on an outpatient basis, unwilling to give consent, and those who died during hospital stay were excluded from the study. No sample size calculation and sampling technique were used. All patients admitted to medical wards with a diagnosis of cardiovascular disorder were included in the study. A total of 236 cardiac patients were admitted to medical wards of JUMC; from these, 200 patients who fulfilled the inclusion criteria were included for the final analysis.

Data collection, procedure, and quality control {#section9-2050312119857353}
-----------------------------------------------

A semi-structured questionnaire was developed by researchers from relevant literatures. Patient chart review and self-report were used to determine various variables. All medications that were prescribed during patient hospital stay (starting from admission to discharge) and administered to the patients were screened for pDDIs. Micromedex 3.0 DRUG-REAX^®^ System (Thomson Reuters Healthcare Inc., Greenwood Village, CO, USA) was used to screen and classify pDDIs. Two trained data collectors interviewed the study participants. Patient charts and medical records were reviewed for the respective information. We used a pill count method as well as medication administration charts for the assessment of drug adherence. If the patient has not received or not administered for less than 95% of his or her prescriptions for unjustified reasons, it will be recorded as "non-adherent."^[@bibr21-2050312119857353],[@bibr22-2050312119857353]^ Before entry to the Statistical Package for Social Sciences (SPSS) for analysis, data were cleared, categorized, compiled, and coded and also checked for completeness and accuracy. Any erroneous, ambiguous, and incomplete data were excluded. The data on DDIs identified were documented. pDDIs were categorized into different levels as follows.

### Onset {#section10-2050312119857353}

1.  *Rapid*. The effect of interaction occurs within 24 h of administration.

2.  *Delayed*. The effect occurs if the interacting combination is administered for more than 24 h, that is, days to week(s).

3.  *Unspecified*. The occurrence of the effect of interaction is not specified.

### Severity {#section11-2050312119857353}

1.  *Major*. There is risk of death and/or medical intervention is required to prevent or minimize serious negative outcomes.

2.  *Moderate*. The effect of interaction can deteriorate patient's condition and may require alteration of therapy.

3.  *Minor*. Slight effects are produced that do not impair the therapeutic outcome.

Data processing and analysis {#section12-2050312119857353}
----------------------------

Data were entered into a computer using EpiData version 3.1 and exported to SPSS version 20.0 for analysis. Logistic regression analyses were used to assess the crude and adjusted effects of seemingly significant predictors of the target outcome. Variables that had a p-value ⩽ 0.25 on univariate analysis were eligible for multivariate logistic regression. All crude odds ratios (CORs) were reported through univariate logistic regression output and adjusted odds ratio (AOR) through multivariate logistic regression. Categorical and continuous data were expressed as percentages and mean ± standard deviations (SDs), respectively. Descriptive statistics were applied for the analysis of patient characteristics, including means, SDs, medians, and percentiles, and categorical variables were analyzed using the chi-square test. A p-value \< 0.05 was considered to be statistically significant.

Ethical consideration {#section13-2050312119857353}
---------------------

Ethical clearance and approval was obtained from the institutional review board (IRB) of Jimma University. The data collected from the JUMC medical wards were preceded by a formal request letter from Jimma University. Written informed consent was obtained from each study participant after clear orientation of the study objective. The raw data were not made available to anyone and not used as the determinant of the participant. All steps in data collection and compilation were conducted and supervised by the researchers. Strict confidentiality was assured through anonymous recording and coding of questionnaires and placed in a safe place. The patient had full right not to participate as well as leave the study at any time during the study.

Results {#section14-2050312119857353}
=======

Medical and medication profiles of 200 hospitalized cardiac patients were evaluated during the study period in terms of pDDIs. Majority of the study participants were male 105 (52.50%), were at the age of ⩾56 years (77; 38.50%), were married (91; 45.50%), live and come from the urban area (107; 53.50%), and were unemployed (104; 52%) ([Table 1](#table1-2050312119857353){ref-type="table"}).

###### 

Baseline sociodemographic characteristics of the study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table1)

  Variables                 Frequency (N)         Percentage     
  ------------------------- --------------------- -------------- ------
  Age (years)               Mean ± SD             42.54 ± 7.89   
  18--35                    58                    29             
  36--55                    65                    32.5           
  ⩾56                       77                    38.5           
  Gender                    Male                  105            52.5
  Female                    95                    47.5           
  Marital Status            Single                40             20
  Married                   91                    45.5           
  Divorced                  27                    13.5           
  Widowed                   42                    21             
  Occupation                Government employee   37             18.5
  Non-government employee   29                    14.5           
  Self-employed             30                    15             
  Unemployed                104                   52             
  Literacy status           No formal education   75             50
  Primary school            52                    27             
  Secondary school          36                    11             
  College and above         37                    12             
  Residency                 Rural                 93             46.5
  Urban                     107                   53.5           
  Monthly income (ETB)      No regular income     100            50
  \<1000                    27                    13.5           
  1000--2000                24                    12             
  2000--3000                28                    14             
  \>3000                    21                    10.5           

JUMC: Jimma University Medical Center; SD: standard deviation; ETB: Ethiopian Birr.

Concerning the study participants' behavioral habit, majority were non-smokers (122; 61%). About 94 (47%) were khat chewer and 58 (29%) were alcoholic. With regard to adherence to prescribed medications, among the study participants, about 89 (45.50%) patients were not fully adherent to their medication ([Table 2](#table2-2050312119857353){ref-type="table"}).

###### 

Behavioral measures of study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table2)

  Variables              Frequency (N)   Percentage   
  ---------------------- --------------- ------------ ------
  Tobacco use history    Ex-smoker       38           19
  Current smoker         40              20           
  Non-smoker             122             61           
  Alcohol use history    Yes             58           29
  No                     142             71           
  Khat chewing history   Yes             94           47
  No                     106             53           
  Herbal medicine use    Yes             55           27.5
  No                     145             72.5         
  Adherence              Adherent        111          55.5
  Not adherent           89              44.5         

JUMC: Jimma University Medical Center.

In about 130 (43.92%) patients, comorbidities originated from infections, followed by hypertension (70; 23.65%) and atrial fibrillation (32; 10.81%). Around 53 (26.50%) study participants were diagnosed with one comorbid condition. The main causes of heart failure were ischemic heart disease accounting for 38.5%, followed by hypertensive heart disease (32.5%) and valvular heart disease (12.5%). The mean number of drugs prescribed per patient in the study population was 7.43 ± 3.86 (range 2--15). The mean duration of hospital stay of patients was 7.63 ± 4.66 (range 5--36) days ([Table 3](#table3-2050312119857353){ref-type="table"}).

###### 

Baseline clinical characteristics of study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table3)

  Variables                         Frequency (N)                                                      Percentage            
  --------------------------------- ------------------------------------------------------------------ --------------------- -------
  Types of comorbidity              Hypertension                                                       70                    23.65
                                    Atrial fibrillation                                                32                    10.81
                                    Infection^[a](#table-fn4-2050312119857353){ref-type="table-fn"}^   130                   43.92
                                    Hyperthyroid                                                       11                    3.72
                                    Diabetes mellitus                                                  20                    6.75
                                    Chronic obstructive pulmonary disease                              6                     2.02
                                    Other^[b](#table-fn5-2050312119857353){ref-type="table-fn"}^       27                    9.12
  Number of diagnosed comorbidity   1                                                                  53                    26.50
                                    2                                                                  60                    30.00
                                    3                                                                  48                    24.00
                                    ⩾4                                                                 39                    19.50
  Cause of heart failure            Valvular heart diseases                                            25                    12.50
                                    Dilated cardiomyopathy                                             17                    8.50
                                    Constrictive pericarditis                                          7                     3.50
                                    Ischemic heart disease                                             77                    38.50
                                    Hypertensive heart disease                                         65                    32.50
                                    Other^[c](#table-fn6-2050312119857353){ref-type="table-fn"}^       9                     4.50
  Hospital stay of patients         Mean ± SD (range), days                                            7.43 ± 3.86 (2--34)   
                                    \<7 days                                                           79                    39.50
                                    ⩾7 days                                                            121                   60.50
  Number of drugs administered      Mean ± SD per patient (range)                                      7.43 ± 3.86 (2--15)   
  2                                 10                                                                 5.00                  
  3--5                              71                                                                 35.50                 
  ⩾5                                119                                                                59.50                 

JUMC: Jimma University Medical Center; SD: standard deviation.

Community-acquired pneumonia and urinary tract infection;

Asthma, dyspepsia and renal disorders.

Hyperthyroidism and renal disorders.

Out of the 673 patients' prescriptions analyzed, 521 prescriptions comprised potential drug interactions and it was found that 967 drug interactions were present. The prevalence rate of pDDIs among cardiac patients admitted to medical wards was 4.83 per patient and 1.44 per prescription regardless of the severity during their hospital stay.

Overall the prevalence rate of pDDIs was 74.41%. About 441 (45.0%) pDDIs were moderate and nearly one-third were major in severity. One-fourth of the pDDIs occurred due to PK interactions. About 496 (51.30%) were delayed in onset and above two-third resulted in cardiovascular system alterations. The risk of hemorrhage and toxicity will occur in up to 273 (28.23) prescriptions. Nearly in one-fourth of the prescriptions, multiple clinical effects will occur due to pDDI. With regard to pDDI management, in about 378 (39.10%) prescriptions, the use of alternative product is warranted. The need for dose adjustment and continued monitoring was for about 279 (28.85%) and 247 (25.54) prescriptions, respectively ([Table 4](#table4-2050312119857353){ref-type="table"}).

###### 

Prevalence of potential drug--drug interactions among study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table4)

  Variables                                           Frequency (N)                        Percentage   
  --------------------------------------------------- ------------------------------------ ------------ -------
  Severity of potential DDIs                          Overall (average per prescription)   967 (1.44)   
  Major                                               316                                  32.68        
  Moderate                                            441                                  45.60        
  Minor                                               210                                  21.72        
  Prevalence with mechanism of interactions           Pharmacokinetic                      245          25.34
  Pharmacodynamic                                     574                                  59.36        
  Unknown                                             148                                  15.30        
  Onset of potential DDI                              Rapid                                373          38.57
  Delayed                                             496                                  51.30        
  Not specified/unknown                               98                                   10.13        
  Possible clinical implications of potential DDIs    Cardiovascular system alterations    653          67.52
  Metabolic alterations                               317                                  32.78        
  Risk of hemorrhage/toxicity                         273                                  28.23        
  Multiple effects                                    241                                  24.92        
  Proposed measures for management of potential DDI   Use of alternatives                  378          39.10
  Dose adjustment                                     279                                  28.85        
  Continue with monitoring                            247                                  25.54        
  Multiple actions                                    63                                   6.51         

JUMC: Jimma University Medical Center; DDI: drug--drug interaction.

From the top 10 pDDIs, drug interaction between aspirin and furosemide occurred in about 173 (33.20%) prescriptions. Drug interaction between omeprazole and clopidogrel accounted for 75 (14.40%) prescriptions. About 288 (55.27%) prescriptions showed a major pDDI from the top 10 DDIs assessed during the study period ([Table 5](#table5-2050312119857353){ref-type="table"}).

###### 

Top 10 major and moderate potential drug--drug interactions with their potential risks among study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table5)

  S. No.   Drug combinations             Potential risks                    Severity   Frequency (%)
  -------- ----------------------------- ---------------------------------- ---------- ---------------
  1        Aspirin + furosemide          Fluid retention                    Moderate   173 (33.20)
  2        Aspirin + enalapril           Renal dysfunction                  Major      157 (30.13)
  3        Aspirin + clopidogrel         Bleeding                           Major      75 (14.40)
  4        Omeprazole + clopidogrel      Decrease effect of clopidogrel     Major      56 (10.75)
  5        Atorvastatin + clopidogrel    Risk of hepatotoxicity             Moderate   49 (9.40)
  6        Enalapril + spironolactone    Hyperkalemia                       Moderate   47 (9.02)
  7        Warfarin + aspirin            Bleeding                           Moderate   38 (7.30)
  8        Simvastatin + azithromycin    Increased risk of rhabdomyolysis   Moderate   37 (7.10)
  9        Clarithromycin + amlodipine   Increased amlodipine exposure      Moderate   32 (6.14)
  10       Warfarin + metronidazole      Decreased effect of warfarin       Moderate   32 (6.14)

JUMC: Jimma University Medical Center.

Associated factors for pDDIs {#section15-2050312119857353}
----------------------------

On the univariate analysis, older age was significantly associated to the occurrence of DDIs (COR (95% confidence interval (CI)): 1.21 (2.04--33.67), p = 0.027). The adjusted analysis also remained in the same direction (AOR (95% CI): 1.067 (2.33--27.12), p = 0.049), indicating older age as an independent predictor for pDDIs' occurrence. Behavioral measures (i.e. being smoker, khat chewer, and alcoholic) was relatively associated with pDDIs' occurrence. Long hospital stay (⩾7 days) was found to be a predictor for DDIs' occurrence (AOR (95% CI): 2.80 (1.71--4.61), p = 0.024). Moreover, polypharmacy was significantly associated with pDDIs' occurrence (COR (95% CI): 1.27 (0.62--2.51), p = 0.055) and it was an independent predictor for DDIs (AOR (95% CI): 1.64 (0.66--4.11), p = 0.041) ([Table 6](#table6-2050312119857353){ref-type="table"}).

###### 

Factors associated with potential drug--drug interactions among study participants at medical wards of JUMC 2017.

![](10.1177_2050312119857353-table6)

  Variables                         Number of patients        COR (95% CI)   p-value   AOR (95% CI)          p-value                         
  --------------------------------- ------------------------- -------------- --------- --------------------- --------- --------------------- -------
  Age                               18--35                    55             3         1.00                            1.00                  
                                    36--55                    63             2         0.98 (0.053--9.32)    0.072     1.03 (0.013--11.45)   0.192
                                    ⩾56                       77             0         1.21 (2.04--33.67)    0.027     1.067 (2.33--7.12)    0.049
  Gender                            Female                    93             2         1.00                            1.00                  
                                    Male                      102            3         0.51 (0.041--43.22)   0.694     0.07 (3.04--30.01)    0.832
  Literacy status                   Had no formal education   75             0         1.00                                                  
                                    Primary school            50             2         0.54 (11.43--19.92)   0.642                           
                                    Secondary school          34             2         0.83 (1.83--7.21)     0.922                           
                                    College and above         37             1         0.61 (0.43--0.88)     0.260                           
  Smoking history                   Non-smoker                107            5         1.00                            1.00                  
                                    Current smoker            40             0         1.14 (0.49--2.51)     0.055     1.23 (0.51--2.98)     0.251
                                    Ex-smoker                 38             0         0.93 (0.31--2.87)     0.241     1.01 (0.31--3.03)     0.344
  Alcohol use history               No                        141            1         1.00                            1.00                  
                                    Yes                       54             4         0.627 (0.25, 1.71)    0.068     1.53 (0.54--4.36)     0.312
  Khat chewing history              No                        104            2         1.00                            1.00                  
                                    Yes                       91             3         1.08 (1.121--2.231)   0.057     1.41 (0. 97--2.66)    0.290
  Hospital stay (days)              \<7                       74             5         1.00                            1.00                  
                                    ⩾7                        121            0         1.13 (0.68--1.87)     0.071     2.80 (1.71--4.61)     0.024
  Number of drugs on prescription   \<5                       77             4         1.00                            1.00                  
                                    ⩾5                        118            1         1.27 (0.62--2.51)     0.055     1.64 (0.66--4.11)     0.041
  Adherence                         Adherent                  109            2         1.00                            1.00                  
                                    Non-adherent              86             3         7.08 (1.25--120.01)   0.062     1.32 (0.70--2.30)     0.49

JUMC: Jimma University Medical Center; COR: crude odds ratio; AOR: adjusted odds ratio; CI: confidence interval; pDDIs: potential drug--drug interactions.

Discussion {#section16-2050312119857353}
==========

This study is the first of its kind to be carried out at JUMC inpatient medical wards. Potential drug interaction occurs when two drugs known to interact are concurrently prescribed, regardless of whether adverse events occur. In actual drug interaction, clinically meaningful alteration of the effect of an object drug occurs as a result of co-administration of another drug (precipitant drug). Potential drug interactions necessarily happen before actual drug interactions.^[@bibr23-2050312119857353]^

The importance of drug interactions in clinical practice primarily involves knowing or predicting those occasions when a potential interaction is likely to pose significant consequences for the patient. To predict the possible consequences of the administration of two or more drugs, health professionals should have practical knowledge of the pharmacological mechanism involved in drug interactions, drugs associated with great risk, and the most susceptible patient group.^[@bibr24-2050312119857353]^ Different strategies can be used to minimize the risks associated with potentially harmful drug combinations, such as reducing exposure to concurrent administration, using an alternative treatment, making a dosage adjustment, and monitoring the patient closely.^[@bibr23-2050312119857353]^

Drug interaction is one of the very important issues in drug therapy, especially in patients with multiple medical conditions, like patients with cardiovascular disorders. The study highlighted the overall prevalence rate of pDDIs (77.41%) from the combinations of the prescribed drugs. This is a high figure that highlights the importance of this previously unstudied problem in our hospital. Our study findings showed a higher prevalence of pDDIs as compared to reports from India (52.17%) among hospitalized patients,^[@bibr25-2050312119857353]^ South India (30.67%),^[@bibr26-2050312119857353]^ Pakistan (52%),^[@bibr27-2050312119857353]^ and Nepal (21.3%).^[@bibr23-2050312119857353]^ The reason for the higher prevalence of pDDIs in our study could be due to consideration of all grades of pDDIs; about two-fifth of our study populations were older patients and we follow the admitted cardiac patients throughout their hospital stay, which may increase drug interaction risks from multiple-drug exposure in inpatients.

In this study, pDDIs are classified on the basis of onset, severity, and evidence of occurrence. Based on the onset of pDDIs, 38.57% are rapid and 51.30% are delayed, and on the basis of severity about 32.68% of pDDIs were major and 45.60% and 21.72% were moderate and minor pDDIs, respectively. Therefore, minor types of pDDIs on the basis of severity and delayed types of pDDIs on the basis of onset were greater in number compared to the others. Delayed type of DDI could take up to several days or weeks to occur, without needing immediate concern or medical intervention.^[@bibr28-2050312119857353]^

Unlike this study, many other studies reported lower percentages of delayed onset pDDIs, ranging from 48.7% to 50%.^[@bibr29-2050312119857353],[@bibr30-2050312119857353]^ But higher percentages of delayed onset pDDIs were reported from Iran (89.2%).^[@bibr31-2050312119857353]^ Therefore, even if there was an interaction occurring during the concomitant administration, it may not manifest itself immediately. If these combinations of drugs were to be continued on an outpatient basis, this could potentially lead to decreased efficacy, leading to therapeutic failures or potential for delayed adverse events. Hence, the duration of concomitant drug use should also be taken into account when prescribing relevant interacting drugs. In addition, the identification of these interactions at the time of discharge is important because the effect of an interaction may not appear until the patient has been transferred to another hospital unit. The greatest concern is that the effect will not appear until after hospital discharge. This situation highlights the importance of the medication reconciliation process for patient safety upon discharge from the hospital admission.

In this study, a higher number of observed pDDIs were due to PD mechanisms (59.36%) compared to PK type of interactions (25.34%). These findings differ from those reported from Nepal and by Sharma et al.,^[@bibr23-2050312119857353]^ Vonbach et al.,^[@bibr32-2050312119857353]^ and Aparasu et al.^[@bibr33-2050312119857353]^ The most common management plan found in this study for most of the drug interactions was using alternative medication and dose adjustment. Despite the importance of PD drug interaction in some scenarios (in synergism cases), it will pose clinically meaningful interactions. For example, the combination of angiotensin-converting enzyme (ACE) inhibitors with potassium-sparing diuretics such as amiloride or spironolactone can increase potassium retention so strongly that life-threatening hyperkalemia ensues. Therefore, patient-specific monitoring is the crucial step in clinical practice.

The mean age in this study was 42.54 ± 7.89 years. Majority (44%) of the patients in this study belonged to the age group ⩾ 55 years and also the pDDIs were widely seen in patients of the same age group. Our study showed similar data as those from South India,^[@bibr34-2050312119857353]^ but are in contrast with those from European countries.^[@bibr32-2050312119857353],[@bibr35-2050312119857353],[@bibr36-2050312119857353]^ This can be explained by the fact that our study enrolled hospitalized patients, where elderly individuals were exposed to more multiple regimens than younger individuals, which in turn increases the risk of pDDIs.

The pDDIs are common in elderly patients during hospitalization. Hence, health professionals give priority to elderly patients, especially to those being treated with polypharmacy for chronic disease, taking drugs with a narrow therapeutic index, and taking drugs metabolized by enzymes susceptible to induction or inhibition. This is because they have the highest probability of experiencing pDDIs with their prescribed medications. Age-related physiological changes and altered PK and PD consequences place elderly patients at a high risk of pDDI-related adverse events. Therefore, by combining their knowledge and skills, health care providers should develop a comprehensive plan to enable the best pharmacotherapy while reducing the risks of drug interactions.^[@bibr37-2050312119857353]^

The average duration of hospital stay in this study was 7.43 ± 3.86 days. It was also seen that there is a relationship between increased prevalence of pDDIs in the population and the increased duration of stay. A chi-square analysis shows that patients who stayed longer than 7 days in hospital had significant pDDIs as compared to earlier discharged patients (p = 0.024). Available studies also have shown that the increased length of stay increases the probability of pDDIs' occurrence.^[@bibr32-2050312119857353],[@bibr38-2050312119857353],[@bibr39-2050312119857353]^ This might be because the chance of taking multiple drugs increases with longer stays in the hospital, which in turn increases the risk for pDDIs.

Polypharmacy is an important factor which leads to pDDIs; the more the number of items per prescription, the more the likelihood of pDDIs' occurrence. This study also showed that the prevalence of pDDIs was associated with the number of drugs administered (p = 0.041). The prevalence of pDDIs in this study was about 59.5% in patients taking polypharmacy. Different studies showed that the number of medications has been shown to be a predictive factor for the occurrence of pDDIs at hospitals.^[@bibr40-2050312119857353][@bibr41-2050312119857353]--[@bibr42-2050312119857353]^ Therefore, this study was in line with different scientific backgrounds in which hospitalized patients contract the likelihood of pDDIs due to severe and multiple illnesses, comorbid conditions, chronic therapeutic regimen, multiple medications, and frequent changes in drug therapy. This shows the importance of paying attention during the hospital stay through close medical monitoring combined with continuous nursing and pharmaceutical care.

Health care providers should be more aware of pDDIs and should collaborate to develop educational programs and improve patients' counseling to avoid/reduce improper use of medications. Our recommendation is to pay more attention for patient's medication list before considering this combination as desirable or undesirable drug interaction.

The limitation of this study is that the sampling method was convenient and the small number of participants which limits the ability to make broader generalizations from the results. Also, the Micromedex drug interaction checker used in this study did not take into consideration the prescribed dose, frequency of administration, and route of administration. However, our study revealed the magnitude of pDDIs among admitted cardiac patients and the need to take proactive measures to reduce these additional burdens on our patients.

Conclusion {#section17-2050312119857353}
==========

This study demonstrated a high prevalence of pDDIs among hospitalized cardiac patients in medical wards due to the complexity of pharmacotherapy. The prevalence rate is directly related to age, number of prescribed drugs, length of hospital stay, history of tobacco use, and khat chewing. PD DDI was the common mechanism of pDDIs. Older age, long hospital stay, and polypharmacy were independent predictors for the occurrence of pDDIs. Therefore, development and implementation of cautionary guidelines and computer-based screening could help physicians and pharmacists to prevent potentially dangerous drug interactions in order to avoid harmful effects on patients.
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